CMND Partners with Hebrew University to Study MEAI with Tirzepatide, Targets $170B Incretin Therapies Market
Clearmind Medicine Inc. Common Shares · Now $3.17
-38% in 1d after detection
Post-detection moves
1h
—
1d
-38%
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS